Press Releases | Y-mAbs Therapeutics, Inc.

Year

Y-mAbs Announces Data to be Presented at 2020 ASCO Annual Meeting

NEW YORK , May 13, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer is pleased to

May 13, 2020

Y-mAbs Announces First Quarter 2020 Financial Results and Recent Corporate Developments

NEW YORK , May 07, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported

May 07, 2020

UPDATE - Y-mAbs to Announce First Quarter 2020 Financial and Operating Results on May 7, 2020

NEW YORK , April 30, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the first quarter ended March 31, 2020 on Thursday, May 7, 2020 , after the close of the U.S. financial markets.

Apr 30, 2020

Y-mAbs Announces Appointment of Laura J. Hamill to its Board of Directors

NEW YORK , April 24, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. , (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Apr 24, 2020

Y-mAbs enters into Worldwide Exclusive License Agreement for SADA Technology – a Novel Radioimmunotherapy Platform

NEW YORK , April 15, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Apr 15, 2020

Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA

NEW YORK , April 01, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Apr 01, 2020

Y-mAbs Announces 2019 Financial Results and Recent Corporate Developments

NEW YORK , March 12, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Mar 12, 2020

Y-mAbs to Announce 2019 Financial and Operating Results on March 12, 2020

NEW YORK , March 05, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its 2019 financial and operating results on Thursday, March 12, 2020 , after the close of the U.S. financial markets.

Mar 05, 2020

Y-mAbs Announces Positive Pre-BLA Meeting with FDA for Omburtamab

NEW YORK , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced

Feb 26, 2020

Y-mAbs Therapeutics To Present At 38th Annual J.P. Morgan Healthcare Conference

NEW YORK , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Jan 07, 2020